Breast Biopsy Market Update 2023: Revenue to Cross USD 2,451 Million by 2030, Exclusive Report

The breast biopsy market is witnessing a significant growth owing to rising awareness about breast cancer and the increasing prevalence of the disease. However, to make this information unique, let’s focus on some interesting developments in the field of breast biopsy.

In recent years, there has been a growing demand for minimally invasive breast biopsy procedures. This has led to the development of advanced technologies such as vacuum-assisted biopsy (VAB) and core needle biopsy (CNB). These techniques are less invasive and provide more accurate results compared to traditional biopsy methods.

Another trend in the breast biopsy market is the use of artificial intelligence (AI) and machine learning (ML) to improve the accuracy of breast cancer diagnosis. AI and ML can analyze large amounts of imaging data to identify abnormalities that may not be visible to the naked eye. This technology can also help in predicting the risk of breast cancer and assist in developing personalized treatment plans.

Additionally, there has been a shift towards using liquid biopsy for breast cancer diagnosis. Liquid biopsy involves analyzing a patient’s blood sample to detect circulating tumor cells and cancer-specific biomarkers. This technique is less invasive and provides a more comprehensive view of a patient’s cancer status.

Inquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/1067

Key Market Players

Ethicon Endo Surgery, Intact Medical Corporation, Galini SRL, Hologic Inc., Leica Biosystems Nussloch GmbH, C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC.

The breast biopsy market is segmented based on product, image guided technology, end user, and region.

Product: The product segment of the breast biopsy market includes vacuum-assisted biopsy, core needle biopsy, and fine needle aspiration biopsy. Among these, the core needle biopsy segment is expected to witness the highest growth during the forecast period due to its higher accuracy and lower false-negative rates.

Image Guided Technology: The breast biopsy market is also segmented based on image guided technology, which includes MRI-guided breast biopsy, ultrasound-guided breast biopsy, mammography-guided stereotactic biopsy, CT-guided biopsy, and other image guided breast biopsy methods. The mammography-guided stereotactic biopsy segment is expected to hold the largest share of the market due to its accuracy and minimal invasiveness.

End User: Based on end user, the breast biopsy market is segmented into hospitals and clinics and diagnostic centers. The hospitals and clinics segment is expected to dominate the market due to the increasing number of breast cancer cases and the availability of advanced diagnostic equipment in hospitals.

Region: Geographically, the breast biopsy market is segmented into Europe, Asia-Pacific, North America, and LAMEA. North America is expected to hold the largest share of the market due to the high prevalence of breast cancer, favorable reimbursement policies, and the presence of a large number of key players in the region. However, the Asia-Pacific region is expected to witness the highest growth during the forecast period due to the increasing awareness about breast cancer and the rising healthcare infrastructure in the region.